Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Pseudomonas aeruginosa AlgR Phosphorylation Status Differentially Regulates Pyocyanin and Pyoverdine Production.

Little AS, Okkotsu Y, Reinhart AA, Damron FH, Barbier M, Barrett B, Oglesby-Sherrouse AG, Goldberg JB, Cody WL, Schurr MJ, Vasil ML, Schurr MJ.

MBio. 2018 Jan 30;9(1). pii: e02318-17. doi: 10.1128/mBio.02318-17.

2.

Expression analysis of the Pseudomonas aeruginosa AlgZR two-component regulatory system.

Pritchett CL, Little AS, Okkotsu Y, Frisk A, Cody WL, Covey CR, Schurr MJ.

J Bacteriol. 2015 Feb 15;197(4):736-48. doi: 10.1128/JB.02290-14. Epub 2014 Dec 8.

3.

Change is good: variations in common biological mechanisms in the epsilonproteobacterial genera Campylobacter and Helicobacter.

Gilbreath JJ, Cody WL, Merrell DS, Hendrixson DR.

Microbiol Mol Biol Rev. 2011 Mar;75(1):84-132. doi: 10.1128/MMBR.00035-10. Review.

4.

Pseudomonas aeruginosa AlgR controls cyanide production in an AlgZ-dependent manner.

Cody WL, Pritchett CL, Jones AK, Carterson AJ, Jackson D, Frisk A, Wolfgang MC, Schurr MJ.

J Bacteriol. 2009 May;191(9):2993-3002. doi: 10.1128/JB.01156-08. Epub 2009 Mar 6.

5.

Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action.

Van Huis CA, Casimiro-Garcia A, Bigge CF, Cody WL, Dudley DA, Filipski KJ, Heemstra RJ, Kohrt JT, Leadley RJ Jr, Narasimhan LS, McClanahan T, Mochalkin I, Pamment M, Peterson JT, Sahasrabudhe V, Schaum RP, Edmunds JJ.

Bioorg Med Chem. 2009 Mar 15;17(6):2501-11. doi: 10.1016/j.bmc.2009.01.063. Epub 2009 Feb 3.

PMID:
19231206
6.

Skim milk enhances the preservation of thawed -80 degrees C bacterial stocks.

Cody WL, Wilson JW, Hendrixson DR, McIver KS, Hagman KE, Ott CM, Nickerson CA, Schurr MJ.

J Microbiol Methods. 2008 Sep;75(1):135-8. doi: 10.1016/j.mimet.2008.05.006. Epub 2008 May 14.

7.

The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor.

Kohrt JT, Bigge CF, Bryant JW, Casimiro-Garcia A, Chi L, Cody WL, Dahring T, Dudley DA, Filipski KJ, Haarer S, Heemstra R, Janiczek N, Narasimhan L, McClanahan T, Peterson JT, Sahasrabudhe V, Schaum R, Van Huis CA, Welch KM, Zhang E, Leadley RJ, Edmunds JJ.

Chem Biol Drug Des. 2007 Aug;70(2):100-12.

PMID:
17683371
8.

Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors.

Van Huis CA, Bigge CF, Casimiro-Garcia A, Cody WL, Dudley DA, Filipski KJ, Heemstra RJ, Kohrt JT, Narasimhan LS, Schaum RP, Zhang E, Bryant JW, Haarer S, Janiczek N, Leadley RJ Jr, McClanahan T, Thomas Peterson J, Welch KM, Edmunds JJ.

Chem Biol Drug Des. 2007 Jun;69(6):444-50.

PMID:
17581239
9.

Binding thermodynamics of substituted diaminopyrimidine renin inhibitors.

Sarver RW, Peevers J, Cody WL, Ciske FL, Dyer J, Emerson SD, Hagadorn JC, Holsworth DD, Jalaie M, Kaufman M, Mastronardi M, McConnell P, Powell NA, Quin J 3rd, Van Huis CA, Zhang E, Mochalkin I.

Anal Biochem. 2007 Jan 1;360(1):30-40. Epub 2006 Oct 30.

PMID:
17113558
10.

The discovery of glycine and related amino acid-based factor Xa inhibitors.

Kohrt JT, Filipski KJ, Cody WL, Bigge CF, La F, Welch K, Dahring T, Bryant JW, Leonard D, Bolton G, Narasimhan L, Zhang E, Peterson JT, Haarer S, Sahasrabudhe V, Janiczek N, Desiraju S, Hena M, Fiakpui C, Saraswat N, Sharma R, Sun S, Maiti SN, Leadley R, Edmunds JJ.

Bioorg Med Chem. 2006 Jul 1;14(13):4379-92. Epub 2006 Mar 10.

PMID:
16529937
11.

Ketopiperazine-based renin inhibitors: optimization of the "C" ring.

Holsworth DD, Cai C, Cheng XM, Cody WL, Downing DM, Erasga N, Lee C, Powell NA, Edmunds JJ, Stier M, Jalaie M, Zhang E, McConnell P, Ryan MJ, Bryant J, Li T, Kasani A, Hall E, Subedi R, Rahim M, Maiti S.

Bioorg Med Chem Lett. 2006 May 1;16(9):2500-4. Epub 2006 Feb 15.

PMID:
16480874
12.

The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex--Part 2.

Kohrt JT, Filipski KJ, Cody WL, Cai C, Dudley DA, Van Huis CA, Willardsen JA, Narasimhan LS, Zhang E, Rapundalo ST, Saiya-Cork K, Leadley RJ, Edmunds JJ.

Bioorg Med Chem Lett. 2006 Feb 15;16(4):1060-4. Epub 2005 Nov 11.

PMID:
16289811
13.

The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex.

Kohrt JT, Filipski KJ, Cody WL, Cai C, Dudley DA, Van Huis CA, Willardsen JA, Rapundalo ST, Saiya-Cork K, Leadley RJ, Narasimhan L, Zhang E, Whitlow M, Adler M, McLean K, Chou YL, McKnight C, Arnaiz DO, Shaw KJ, Light DR, Edmunds JJ.

Bioorg Med Chem Lett. 2005 Nov 1;15(21):4752-6.

PMID:
16125385
14.

Discovery of novel non-peptidic ketopiperazine-based renin inhibitors.

Holsworth DD, Powell NA, Downing DM, Cai C, Cody WL, Ryan JM, Ostroski R, Jalaie M, Bryant JW, Edmunds JJ.

Bioorg Med Chem. 2005 Apr 1;13(7):2657-64.

PMID:
15755665
15.

The discovery and preparation of disubstituted novel amino-aryl-piperidine-based renin inhibitors.

Cody WL, Holsworth DD, Powell NA, Jalaie M, Zhang E, Wang W, Samas B, Bryant J, Ostroski R, Ryan MJ, Edmunds JJ.

Bioorg Med Chem. 2005 Jan 3;13(1):59-68.

PMID:
15582452
16.

Practical synthesis of 1-aryl-6-(hydroxymethyl)-2-ketopiperazines via a 6-exo amide-epoxide cyclization.

Powell NA, Ciske FL, Clay EC, Cody WL, Downing DM, Blazecka PG, Holsworth DD, Edmunds JJ.

Org Lett. 2004 Oct 28;6(22):4069-72.

PMID:
15496101
17.

Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.

Willardsen JA, Dudley DA, Cody WL, Chi L, McClanahan TB, Mertz TE, Potoczak RE, Narasimhan LS, Holland DR, Rapundalo ST, Edmunds JJ.

J Med Chem. 2004 Jul 29;47(16):4089-99.

PMID:
15267248
18.

Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.

Dudley DA, Bunker AM, Chi L, Cody WL, Holland DR, Ignasiak DP, Janiczek-Dolphin N, McClanahan TB, Mertz TE, Narasimhan LS, Rapundalo ST, Trautschold JA, Van Huis CA, Edmunds JJ.

J Med Chem. 2000 Nov 2;43(22):4063-70.

PMID:
11063603
19.

Progress in the development of inhibitors of SH2 domains.

Cody WL, Lin Z, Panek RL, Rose DW, Rubin JR.

Curr Pharm Des. 2000 Jan;6(1):59-98. Review.

PMID:
10637372
20.

The design of potent and selective inhibitors of thrombin utilizing a piperazinedione template: part 2.

Cody WL, Augelli-Szafran CE, Berryman KA, Cai C, Doherty AM, Edmunds JJ, He JX, Narasimhan LS, Penvose-Yi J, Plummer JS, Rapundalo ST, Rubin JR, Van Huis CA, Leblond L, Winocour PD, Siddiqui MA.

Bioorg Med Chem Lett. 1999 Sep 6;9(17):2503-8.

PMID:
10498197
21.

The design of potent and selective inhibitors of thrombin utilizing a piperazinedione template: part 1.

Cody WL, Cai C, Doherty AM, Edmunds JJ, He JX, Narasimhan LS, Plummer JS, Rapundalo ST, Rubin JR, Van Huis CA, St-Denis Y, Winocour PD, Siddiqui MA.

Bioorg Med Chem Lett. 1999 Sep 6;9(17):2497-502.

PMID:
10498196
22.

N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers.

Hu LY, Ryder TR, Rafferty MF, Cody WL, Lotarski SM, Miljanich GP, Millerman E, Rock DM, Song Y, Stoehr SJ, Taylor CP, Weber ML, Szoke BG, Vartanian MG.

Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12.

PMID:
10206559
23.

Potent and selective bicyclic lactam inhibitors of thrombin: Part 3: P1' modifications.

Plummer JS, Berryman KA, Cai C, Cody WL, DiMaio J, Doherty AM, Eaton S, Edmunds JJ, Holland DR, Lafleur D, Levesque S, Narasimhan LS, Rubin JR, Rapundalo ST, Siddiqui MA, Susser A, St-Denis Y, Winocour P.

Bioorg Med Chem Lett. 1999 Mar 22;9(6):835-40.

PMID:
10206546
24.

Potent and selective bicyclic lactam inhibitors of thrombin: Part 2: P1 modifications.

Plummer JS, Berryman KA, Cai C, Cody WL, DiMaio J, Doherty AM, Edmunds JJ, He JX, Holland DR, Levesque S, Kent DR, Narasimhan LS, Rubin JR, Rapundalo ST, Siddiqui MA, Susser AJ, St-Denis Y, Winocour PD.

Bioorg Med Chem Lett. 1998 Dec 1;8(23):3409-14.

PMID:
9873743
25.

In vitro stability and intestinal absorption characteristics of hexapeptide endothelin receptor antagonists.

Han HK, Stewart BH, Doherty AM, Cody WL, Amidon GL.

Life Sci. 1998;63(18):1599-609.

PMID:
9806213
26.

Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-beta receptor and possess cellular activity.

Eaton SR, Cody WL, Doherty AM, Holland DR, Panek RL, Lu GH, Dahring TK, Rose DR.

J Med Chem. 1998 Oct 22;41(22):4329-42.

PMID:
9784108
28.
29.

Functional activity of new C-terminal cyclic-neurotensin fragment analogs.

Akunne HC, Darling S, Zoski K, Sefler AM, He JX, Sawyer TK, Pugsley TA, Cody WL.

Neuropeptides. 1996 Jun;30(3):213-8.

PMID:
8819144
30.

In vitro assessment of oral delivery for hexapeptide endothelin antagonists.

Stewart BH, Reyner EL, Tse E, Hayes RN, Werness S, He JX, Cody WL, Doherty AM.

Life Sci. 1996;58(12):971-82.

PMID:
8786709
31.

Permeability of the blood-brain barrier to the neurotensin8-13 analog NT1.

Banks WA, Wustrow DJ, Cody WL, Davis MD, Kastin AJ.

Brain Res. 1995 Oct 9;695(1):59-63.

PMID:
8574648
32.

Structure-activity studies of phosphorylated peptide inhibitors of the association of phosphatidylinositol 3-kinase with PDGF-beta receptor.

Ramalingam K, Eaton SR, Cody WL, Lu GH, Panek RL, Waite LA, Decker SJ, Keiser JA, Doherty AM.

Bioorg Med Chem. 1995 Sep;3(9):1263-72.

PMID:
8564419
33.

Structure-activity relationships of the potent combined endothelin-A/endothelin-B receptor antagonist Ac-DDip16-Leu-Asp-Ile-Ile-Trp21: development of endothelin-B receptor selective antagonists.

Cody WL, He JX, DePue PL, Waite LA, Leonard DM, Sefler AM, Kaltenbronn JS, Haleen SJ, Walker DM, Flynn MA, et al.

J Med Chem. 1995 Jul 21;38(15):2809-19.

PMID:
7636842
34.

Agonist properties of a stable hexapeptide analog of neurotensin, N alpha MeArg-Lys-Pro-Trp-tLeu-Leu (NT1).

Akunne HC, Demattos SB, Whetzel SZ, Wustrow DJ, Davis DM, Wise LD, Cody WL, Pugsley TA, Heffner TG.

Biochem Pharmacol. 1995 Apr 18;49(8):1147-54.

PMID:
7748196
35.

Pharmacological differences between rat and human endothelin B receptors.

Reynolds EE, Hwang O, Flynn MA, Welch KM, Cody WL, Steinbaugh B, He JX, Chung FZ, Doherty AM.

Biochem Biophys Res Commun. 1995 Apr 17;209(2):506-12.

PMID:
7733918
36.

Design and structure-activity relationships of C-terminal cyclic neurotensin fragment analogues.

Sefler AM, He JX, Sawyer TK, Holub KE, Omecinsky DO, Reily MD, Thanabal V, Akunne HC, Cody WL.

J Med Chem. 1995 Jan 20;38(2):249-57.

PMID:
7830267
37.

The development of potent peptide agonists and antagonists for the endothelin receptors.

Cody WL, Doherty AM.

Biopolymers. 1995;37(2):89-104. Review.

PMID:
7893949
38.

Effects of selective endothelin antagonists on the hemodynamic response to cyclosporin A.

Davis LS, Haleen SJ, Doherty AM, Cody WL, Keiser JA.

J Am Soc Nephrol. 1994 Jan;4(7):1448-54.

40.

Characterization of endothelins as chemoattractants for human neutrophils.

Wright CD, Cody WL, Dunbar JB Jr, Doherty AM, Hingorani GP, Rapundalo ST.

Life Sci. 1994;55(21):1633-41.

PMID:
7968238
41.

Multiple and combinatorial peptide synthesis. Chemical development and biological applications.

Andrews PC, Leonard DM, Cody WL, Sawyer TK.

Methods Mol Biol. 1994;36:305-28. Review. No abstract available.

PMID:
7535162
42.

Structure-activity relationships of C-terminal endothelin hexapeptide antagonists.

Doherty AM, Cody WL, DePue PL, He JX, Waite LA, Leonard DM, Leitz NL, Dudley DT, Rapundalo ST, Hingorani GP, et al.

J Med Chem. 1993 Sep 3;36(18):2585-94.

PMID:
8410970
43.

Truncated analogues of endothelin and sarafotoxin are selective for the ETB receptor subtype.

Heyl DL, Cody WL, He JX, Flynn MA, Welch KM, Reynolds EE, Doherty AM.

Pept Res. 1993 Sep-Oct;6(5):238-41.

PMID:
8257799
44.

Multiple binding modes for the receptor-bound conformations of cyclic AII agonists.

Plucinska K, Kataoka T, Yodo M, Cody WL, He JX, Humblet C, Lu GH, Lunney E, Major TC, Panek RL, et al.

J Med Chem. 1993 Jun 25;36(13):1902-13.

PMID:
8515427
45.

In vitro and in vivo studies with a series of hexapeptide endothelin antagonists.

Doherty AM, Cody WL, He JX, DePue PL, Cheng XM, Welch KM, Flynn MA, Reynolds EE, LaDouceur DM, Davis LS, et al.

J Cardiovasc Pharmacol. 1993;22 Suppl 8:S98-102.

PMID:
7510009
46.

Design of a functional hexapeptide antagonist of endothelin.

Cody WL, Doherty AM, He JX, DePue PL, Rapundalo ST, Hingorani GA, Major TC, Panek RL, Dudley DT, Haleen SJ, et al.

J Med Chem. 1992 Aug 21;35(17):3301-3. No abstract available. Erratum in: J Med Chem 1993 Jan 22;36(2):304.

PMID:
1324321
47.

Monocyclic endothelins: examination of the importance of the individual disulfide rings.

Cody WL, Doherty AM, He XQ, Rapundalo ST, Hingorani GP, Panek RL, Major TC.

J Cardiovasc Pharmacol. 1991;17 Suppl 7:S62-4.

PMID:
1725434
48.

Structure-activity studies of the C-terminal region of the endothelins and the sarafotoxins.

Doherty AM, Cody WL, Leitz NL, DePue PL, Taylor MD, Rapundalo ST, Hingorani GP, Major TC, Panek RL, Taylor DG.

J Cardiovasc Pharmacol. 1991;17 Suppl 7:S59-61.

PMID:
1725433
49.

Isolation, identification, and characterization of a palladium complex in the catalytic deprotection of a protected peptide.

Heavner GA, Cody WL, Crowther J, Duhl-Emswiler B, May K, Salomons P, Pascone J.

Int J Pept Protein Res. 1990 Aug;36(2):188-92.

PMID:
2272755
50.

Alpha-melanocyte stimulating hormone message and inhibitory sequences: comparative structure-activity studies on melanocytes.

Sawyer TK, Staples DJ, Castrucci AM, Hadley ME, al-Obeidi FA, Cody WL, Hruby VJ.

Peptides. 1990 Mar-Apr;11(2):351-7.

PMID:
2162535

Supplemental Content

Support Center